Embed Size (px)
Citation preview
Cancer Therapy Re-imagined.
NeoTherma Oncology
1/13/2017 NEOTHERMA ONCOLOGY CONFIDENTIAL2
Company: developmental stage medical device company with a disruptive Thermal Treatment (TTx) system for deep solid tumors
Technology: next generation hyperthermia (HT) based on nonionizing electromagnetic field producing ‘fever-range’ temperatures in solid tumors
Therapeutic Effect: increases blood perfusion to the tumor micro-environment, reverses radiotherapy-resistant hypoxia, promotes therapeutic immune response
Pipeline: pancreatic adenocarcinoma (PDAC), followed by head & neck cancer (HNC) and a variety of solid tumors based on strategic partnership opportunities
Potential: pharmaceutical returns from a medical device-level investment
RCT Evidence: HT Effectively Treats a Variety of Cancers
NEOTHERMA ONCOLOGY CONFIDENTIAL 31/13/2017
“The few, but impressive trials are evidence that this is not just an anecdotal technology, but one that warrants continued investment and investigation. The studies’ improvements in tumor response would generally be hailed a success had they been a pharmaceutical product… It is time that this technology is given the attention it deserves.
If Works, Why Don’t More Clinicians Use It?
1/13/2017 NEOTHERMA ONCOLOGY CONFIDENTIAL 4
Text
Ineffective Deep Tumor Heating
Frequent Skin & SubQ Fat Burns
Lack of Integration into Clinical Workflow
Inadequate Assurance of Tumor Heating
Hospital Setup Costs: Faraday-Caged Suite
Poor Coverage & Reimbursement
Deterrents to Use (Current HT Systems)
Finally, Vectron Hits the Target
Inductive RF Field with Switched Array Controlled with Realtime Thermography
Fits into 1.5/3.0 T MRIs and MRI Suites w/o Costly Retrofit
mHT Reduces Burn Potential While Promoting Immune Response; Plus, Clinical Validation Is Addressing Specific Disease Indications
1/13/2017 NEOTHERMA ONCOLOGY CONFIDENTIAL 5
Vectra ‘Fits’ in 90% of MRI Suites
1/13/2017 NEOTHERMA ONCOLOGY CONFIDENTIAL 6
Vectra TTx RF generator situated in conventional MRI Equipment Room with treatment monitor & dashboard in MRI Control Room
Vectra TTx body coil seamlessly integrates TTx RF applicators with MRI reception antennas
Compatible with 90% of 1.5T & 3.0T MRI global installed base
Evidence HT Is an Effective PDAC Adjuvant
NEOTHERMA ONCOLOGY CONFIDENTIAL 7
36% Improvement
in Median Survival (OS)
1/13/2017
33% Increased
Overall Survival (OS)
1/13/2017 NEOTHERMA ONCOLOGY CONFIDENTIAL 8
Investment Opportunity
NeoTherma Oncology invites qualified investors to explore an opportunity to participate in its convertible note ‘B Round’ anticipated to close by 2Q2017.
The round represents an opportunity to participate in the immunotherapy cancer treatment revolution - the lead for the round has been identified.
Funding will provide NTO the runway necessary to complete animal preclinical studies and obtain USFDA Investigational Device Exemption (IDE) approval to conduct its first-in-humans investigation.
Together, we can change the way cancer is treated.
Contact Dr. Michael Wandell (206.790.0120, [email protected]), or Chris Stevens (316-648-2395, [email protected])
1/13/2017 NEOTHERMA ONCOLOGY CONFIDENTIAL 9
Website
Help us change the way cancer is treated.
